March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology
In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.
In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.
Nadofaragene firadenovec led to durable antitumor activity in BCG-unresponsive NMIBC either with CIS or papillary disease, according to 5-year data from the phase 3 Study…
Key Points. Patients with SD/PD to 1L therapy have lower RRs to 2L therapy and poor outcomes compared to other subgroups of primary refractory diseaseWe…
The U.S. Preventive Services Task Force just dropped updated breast cancer screening guidelines.
Nadofaragene firadenovec maintained its durable clinical activity at 5 years in patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer.
After Sam Gee was diagnosed with melanoma at age 14, he underwent surgery and several rounds of immunotherapy. Soon after he was declared cancer-free, his…
Key Points. This was a prospective long term follow-up study including 14530 PBSC and 7123 BM volunteer unrelated donors from the NMDP.PBSC and BM donors…
Adam J. Lamble, Liora M. Schultz, Khanh Nguyen, Emily M Hsieh, Kevin McNerney, Rayne H Rouce, Rebecca A Gardner, Sara Ghorashian, Nirali N Shah, Shannon…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
No new agent has improved overall survival in patients with unresectable or metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy. In this phase 3,…
A medical expert delves into various aspects of second-line therapies, including dose reductions, potential adverse reactions, and the possibility of transfusions, all of which are…